iOnctura has begun a randomized phase 1/2 study investigating its lead asset, roginolisib, in combination with dostarlimab, ...

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for Amgen’s Tepezza ...

UCB has announced that its developmental treatment DoxTM, a combination of doxecitine and doxribtimine, has been granted ...

The Americas Awards are excited to introduce a new category, Clinical Trial Administrator. This category is designed to ...

Janssen-Cilag International NV, a Johnson & Johnson company, has submitted an application to the European Medicines Agency ...

Chiesi UK and Ireland and Wirral Primary Care Collaborative (WPCC) have launched COMET, a programme designed to enhance early ...

NICE reviewed various technologies and recommended DERM as the only AI tool suitable for NHS use. It is the first dermatology ...

Regeneron Pharmaceuticals has announced that the European Commission has conditionally approved Lynozyfic (linvoseltamab) for ...

Janssen-Cilag International NV, a Johnson & Johnson company, has submitted an application to the European Medicines Agency (EMA) to extend the marketing authorisation for RYBREVANT (amivantamab) with ...

Groundbreaking research has identified over 900 genetic links to osteoarthritis, including 500 previously undiscovered, in a ...

Argenx has announced that the Committee for Medicinal Products for Human Use (CHMP) has recommended European Commission (EC) ...